An investor-scientist with experience in medicinal chemistry, drug development, and commercialization.
Jim Trenkle is currently Head of Investments at Sanofi Ventures and has a background in R&D, commercialization, and early-stage biotech investing. Prior to joining Sanofi, Jim was part of the early team at Pivotal bioVenture Partners in San Francisco. He began his career with Gilead Sciences where he held positions of increasing responsibility in medicinal chemistry, project and portfolio management, and commercial strategy, largely focused on hepatitis C and other liver diseases. Jim holds a BS in Honors Chemistry from University of Michigan, a PhD in Organic Chemistry from Massachusetts Institute of Technology, and an MBA from University of California Berkeley, Haas School of Business.